Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Grant revenue $ 7,466 $ 86,047 $ 37,653 $ 131,521
Operating expenses:        
Research and development 769,350 2,777,068 4,448,623 8,660,761
General and administrative 1,332,562 1,215,498 3,697,609 3,592,361
Total operating expenses 2,101,912 3,992,566 8,146,232 12,253,122
Loss from operations (2,094,446) (3,906,519) (8,108,579) (12,121,601)
Other income (expense):        
Interest income 50,613 41,634 171,768 68,909
Interest expense (14,170) (5,228) (18,360) (9,290)
Other income 45,118 46,863 11,333
Total other income, net 81,561 36,406 200,271 70,952
Loss before income taxes (2,012,885) (3,870,113) (7,908,308) (12,050,649)
Income tax benefit
Net loss $ (2,012,885) $ (3,870,113) $ (7,908,308) $ (12,050,649)
Basic net loss per share $ (0.85) $ (1.99) $ (3.70) $ (6.21)
Diluted net loss per share $ (0.85) $ (1.99) $ (3.70) $ (6.21)
Weighted average shares used to compute basic net loss per share 2,356,065 1,945,747 2,136,340 1,941,858
Weighted average shares used to compute diluted net loss per share 2,356,065 1,945,747 2,136,340 1,941,858